unbelievable day in biotech today and this looks like it will close red. no sellers? you mean no buyers!
if anyone doesnt take their profit today that might be a big mistake IMO
one bad day in the overall market or biotech in the next couple of days this will lose all recent gains or a good chunk of them
you have to think they will do an offering in this post EU filing euphoria and the launch. no near term catalysts, no real revenue and huge cash burn per Q they are going to need to do it soon so cash pile doesn't fall too low.
The move this has made this week is baffling for me. they filled like 220 prescriptions? they couldn't even find enough patients for the trial for a while. market is tiny for them. is this a classic bull trap?
couple more months and we'll know how wrong he is
excluding the HETLIOZ income, which won't cover op expenses. don't know if they will raise soon but must come soon in one of these pops. the Europe catalyst is not until Q1 2015 so might be a good time
was expected as was combination of already approved products. question is now how big is the market for the product and can it hold the pop?
history says maybe its a better idea to take profits
seems weird that the company hasn't even announced the date of pdufa though. I'm sure there isn't an issue, its pretty certain to get approved unless there are some manufacturing issues. just seems weird theres no word from the company. if there is a CRL, which must be unlikely, its going back to the 4s
I think its a very unusual situation that an Adcom has been convened in response to an appeal for a CRL. the CRL was issued because the FDA wanted further data for safety concerning adverse potential heart AE, but Salix and PGNX feel they were wrong to do this and have that data, the Adcom will give them a chance to present their case. i think the FDA wants to approve the expansion, there have been no CV AE in its current usage so they may ask for post expansion safety trials but i believe it will get approved. Its just too unlikely that they would call an Adcom, which is an unusual move, only to deny again. Why not just deny again and save everyone time and trouble?
under where? u were soiling your underwear on friday, go on, admit it. how can my short be underwater since it hit 11 on that over done pop?
this is going lower, you have been scammed. they rigged the trial, paid themselves a million bucks and then the whole company had a holiday day. who does that?
Just as expected, and i know you were tearing out your hair today when jt started to really drop. couldn't hold 10.....overall biotech gets back to its downtrend its timberrrrrr for BCRX
we may hear that timeline for the imaging agent
More positive news!
Daniel Petrylak, M.D., Professor of Medical Oncology at Yale Cancer Center and a lead investigator in the trial, will present the poster, "A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC)." The highlights session will be held on Saturday, May 31, beginning at 1:15 p.m. CT.